News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
Celltrion has shelved plans for a third biomanufacturing plant at its site in Incheon in favour of an overseas site it says will help ensure biosimilar supply.
NEWS IN BRIEF
The Sygnis subsidiary has extended its antibody labelling service to allow for scalability and bulk production of antibodies.
Glythera has signed a licensing deal to develop drug conjugates using Avacta’s Affimer technology.